Antoni Ribas - Concepedia

Author

Antoni Ribas

University of California, Los Angeles ORCID

Also Known As

A Alomar Ribas, A Ribas, A. Ribas, Andrew T. Magis, Antoni -. Ribas, Antoni Ribas, Antoni Ribas (49231), Arbel D. Tadmor, George Peoples, Herlyn, Meenhard

1.7K

Publications

160.6K

Citations

157

H-Index

206

Concepts

All Affiliations

University of California, Los Angeles UCLA Jonsson Comprehensive Cancer Center The University of Texas MD Anderson Cancer Center The University of Sydney Melanoma Institute Australia

About

Antoni Ribas is an author at University of California, Los Angeles specializing in medicine, immunology, and immunotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	84	215	51.3K
2	Health Sciences	24	37	3.7K
3	Engineering	10	10	3.5K
4	Public Health	3	3	79
5	Natural Sciences	1	1	70

Antoni Ribas

456

Publications

129K

Citations

143

H-Index

Page 1

	Year	Citations
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation Paul B. Chapman, Axel Hauschild, Caroline Robert, New England Journal of Medicine	2011	7.6K
PD-1 blockade induces responses by inhibiting adaptive immune resistance Paul C. Tumeh, Christina L. Harview, Jennifer H. Yearley, Nature MedicineImmunologyTumor ImmunityAutoimmunityImmunomodulation	2014	6.5K
Pembrolizumab versus Ipilimumab in Advanced Melanoma Caroline Robert, Jacob Schachter, Georgina V. Long, New England Journal of Medicine	2015	5.7K
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma Alexandra Snyder, Vladimir Makarov, Taha Merghoub, New England Journal of Medicine	2014	4.3K
IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade Mark Ayers, Jared Lunceford, Michael Nebozhyn, Journal of Clinical Investigation	2017	3.7K
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma Keith T. Flaherty, Igor Puzanov, Kevin B. Kim, New England Journal of Medicine	2010	3.5K
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma Omid Hamid, Caroline Robert, Adil Daud, New England Journal of Medicine	2013	3.4K
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma Jesse M. Zaretsky, Ángel García-Díaz, Daniel Sanghoon Shin, New England Journal of Medicine	2016	3.1K
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib Caroline Robert, Bogusława Karaszewska, Jacob Schachter, New England Journal of Medicine	2014	2.6K
Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles Mark E. Davis, Jonathan E. Zuckerman, Chung Hang Jonathan Choi, Nature Targeted NanoparticlesNanomedicineNanotherapeuticsEngineeringMedicine	2010	2.5K

Page 1